ReviewFrontiers in medicine2026
Pyroptosis in premature ovarian insufficiency: pathogenic mechanisms, pathway crosstalk, and therapeutic strategies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian insufficiency (POI) is characterised by pathological loss of ovarian function in women younger than 40 years, resulting in premature exhaustion of the ovarian follicle pool and impaired fertility. Although apoptosis has long been considered the dominant mechanism driving granulosa cell (GC) death and follicular atresia, it does not fully explain the severe inflammatory microenvironment and tissue fibrosis observed during POI progression. Recently, pyroptosis, a proinflammatory form of programmed cell death mediated by the gasdermin family, has emerged as a critical driver of ovarian injury. This review comprehensively summarises the core mechanisms of pyroptosis across different POI aetiologies, with particular emphasis on the role of the NLRP3/caspase-1/GSDMD axis, the caspase-3/GSDME-mediated apoptosis-to-pyroptosis switch, and their multi-layered regulation by post-translational modifications, including S-palmitoylation, ubiquitination, and phosphorylation. We further discuss the complex molecular crosstalk between pyroptosis and other programmed cell death pathways, including apoptosis, ferroptosis, and autophagy, highlighting their synergistic roles in amplifying intraovarian inflammation. Finally, we evaluate emerging therapeutic strategies targeting pyroptosis, including mitochondrial reactive oxygen species scavengers, specific NLRP3/caspase-1 inhibitors, modulators of GSDMD post-translational modifications, and mesenchymal stem cell-derived exosome therapies. Collectively, these findings provide novel insights into POI pathogenesis and support the development of precise, non-hormonal therapeutic interventions to rescue the ovarian reserve and protect female reproductive health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.